Fresh analysis reveals that people who stop using new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise regimens.
Published data in a major health publication points out that while overweight people can lose substantial amounts of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these medications must be cognizant of the risk of quick rebound weight gain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
That rate of regain implies a return to starting weight within about a year and a half.
Comparing Treatments
The analysis, which examined dozens of trials involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with older methods.
Scientists note that individuals who shed pounds through dieting usually experience a slower weight regain—around 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Nutrition scientists suggest the mode of action of the injections explains the heightened regain.
The injections mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone concentrations far above than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this medication means hunger is uncontrolled, making excessive eating a significant risk."
A Lifelong Condition?
The NHS suggest the injections for people with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians say that, considering the likelihood of weight regain, the treatment should be considered ongoing.
This opinion is echoed by pharmaceutical companies, who note that the findings "highlight the chronic character of obesity," similar to managing diseases like diabetes.
Patient Testimonies
Individuals who have stopped the jabs explain a intense resurgence of hunger.
"I experienced something activating and you're instantly ravenous," described a patient.
The struggle is exacerbated if patients have not established sustainable lifestyle or habit changes during therapy.
Growing Use
Survey data indicate that millions of adults in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is higher among females than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent fix and lasting health benefits relies on ongoing behavioural management.
